BRAF and non-small cell lung carcinoma: The most frequent mutation is V600E in class I, which occurs in 35%–50% of all BRAF mutations in NSCLC, and the efficacy of dabrafenib plus trametinib has been shown clinically in advanced NSCLC patients.1, 2, 7